Abstract

We fabricated CaCO3-coated vesicles as drug carriers that release their cargo under a weakly acidic condition. We designed and synthesized a peptide lipid containing the Val-His-Val-Glu-Val-Ser sequence as the hydrophilic part, and with two palmitoyl groups at the N-terminal as the anchor groups of the lipid bilayer membrane. Vesicles embedded with the peptide lipids were prepared. The CaCO3 coating of the vesicle surface was performed by the mineralization induced by the embedded peptide lipid. The peptide lipid produced the mineral source, CO32−, for CaCO3 mineralization through the hydrolysis of urea. We investigated the structure of the obtained CaCO3-coated vesicles using transmission electron microscopy (TEM). The vesicles retained the spherical shapes, even in vacuo. Furthermore, the vesicles had inner spaces that acted as the drug cargo, as observed by the TEM tomographic analysis. The thickness of the CaCO3 shell was estimated as ca. 20 nm. CaCO3-coated vesicles containing hydrophobic or hydrophilic drugs were prepared, and the drug release properties were examined under various pH conditions. The mineralized CaCO3 shell of the vesicle surface was dissolved under a weakly acidic condition, pH 6.0, such as in the neighborhood of cancer tissues. The degradation of the CaCO3 shell induced an effective release of the drugs. Such behavior suggests potential of the CaCO3-coated vesicles as carriers for cancer therapies.

Highlights

  • Cancer is the leading cause of death for humankind

  • We considered that the vesicle remained spherical and the Val-His-Val-Glu-Val-Ser sequence of the peptide lipid presented on the outer surface of the vesicle hydrolyzed urea to form the CaCO3 shell

  • We considered that the CaCO3 -coated vesicles act as environmentally responsive drug delivery system (DDS) carriers, with the advantage that the CaCO3 shells dissolve under acidic conditions

Read more

Summary

Introduction

Therapies for cancer are surgery, drug, radiation, etc. Molecular-targeted drugs [1,2] and immune checkpoint inhibitors [3,4] have been developed and are being used in drug therapies. These drugs suppress side effects and achieve high anti-cancer effects; these drugs are very expensive. Many drugs are abandoned in the development stage due to their significant side effects despite their high efficacy. The drug delivery system (DDS) has been refocused to enable the use of these drugs with prominent side-effects. Polymer micelles [5,6], dendrimers [7,8,9], hydrogels [10,11,12,13], and mesoporous nanoparticles [14,15,16]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call